Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $288000.0.

  • Protalix BioTherapeutics' Other Non Operating Income rose 9072.85% to $288000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 2941.18%. This contributed to the annual value of $1.3 million for FY2024, which is 2286.22% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Other Non Operating Income stood at $288000.0 for Q3 2025, which was up 9072.85% from $272000.0 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Other Non Operating Income ranged from a high of $1.8 million in Q4 2022 and a low of -$2000.0 during Q4 2021
  • Over the past 5 years, Protalix BioTherapeutics' median Other Non Operating Income value was $288000.0 (recorded in 2025), while the average stood at $395105.3.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 10253.16% in 2021, then skyrocketed by 8850000.0% in 2022.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Other Non Operating Income stood at -$2000.0 in 2021, then skyrocketed by 88500.0% to $1.8 million in 2022, then plummeted by 79.58% to $361000.0 in 2023, then plummeted by 68.7% to $113000.0 in 2024, then surged by 154.87% to $288000.0 in 2025.
  • Its last three reported values are $288000.0 in Q3 2025, $272000.0 for Q2 2025, and $419000.0 during Q1 2025.